RNAi

March 27, 2026 Five Things to Know about TRITON-CM & How Community Insight is Shaping the Future of ATTR- ... TRITON-CM, Alnylam's Phase 3 clinical trial evaluating nucresiran, a third-generation investigational RNAi therapeutic for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), represents one of the largest global studies ever conducted in this disease. Read More ›
March 26, 2026 Alnylam Awarded 2026 Scientific Impact Award by MassBio Alnylam was recognized by Mass Bio for its pioneering work in RNA interference and the development of RNAi therapeutics as an innovative new class of medicines. Read More ›
December 17, 2025 Alnylam Announces Major Expansion of U.S. Pharmaceutical Manufacturing Facility $250 million investment will add new capacity and siRNA enzymatic ligation capabilities to Alnylam's Norton, Massachusetts site Read More ›
September 30, 2025 How Alnylam’s Manufacturing Investments Bring RNAi Therapeutics to More Patients, Faster Translating our pioneering work in RNAi not only requires innovation in the lab - it requires innovation in how we make our medicines. Read More ›
August 26, 2025 RNAi Therapeutics: 5 Things You Should Know about this Innovative Class of Medicines What is RNAi and what do RNAi therapeutics do? Here are 5 things you should know! Read More ›
February 21, 2025 A New Therapeutic Approach Seeks to Silence Devastating Neurological Diseases Exploring the potential of RNAi therapeutics to tackle brain diseases with few or no treatments Read More ›
January 12, 2025 Alnylam's Kevin Fitzgerald, PhD on The Long Run Podcast - The Past and Future of RNAi Ther ... Alnylam Chief Scientific Officer, Kevin Fitzgerald, PhD recently spoke with Luke Timmerman of The Long Run podcast about the past & future of RNAi therapeutics Read More ›
September 26, 2024 Confronting the World’s Leading Killer with a New Therapeutic Approach For Xicang Guo and Jiaming Zhang, one particular condition remains stubbornly beyond their control – hypertension, also known as high blood pressure. Read More ›
September 12, 2024 RNAi Therapeutics, from Possibility to Patients The story of an innovative approach to silencing disease that’s improving lives and changing expectations for medicine. Read More ›
August 9, 2023 RNAi Therapeutics on the European Pharmaceutical Review Podcast Paul Nioi, PhD, VP of Discovery and Translational Research discussed RNAi therapeutics on the The European Medical Review Podcast. Read More ›
Subscribe to RNAi